🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT06993792
Active, not recruiting Phase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

NCT06993792 · tracked via the Priya Life Science USA tracker
Sponsor
Eli Lilly and Company
Phase
Phase 3
Started
2025-05-15
Last updated
2026-07-31

Condition(s) studied

ObesityOverweightType 2 Diabetes

Investigational drug(s) / intervention(s)

OrforglipronPlacebo

Orforglipron: Administered orally

Placebo: Administered orally

Study summary

The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
There are no specific eligibility criteria for the Master Protocol. * See study GZP1 for eligibility criteria relevant to participants with obesity and overweight without type 2 diabetes * See study GZP2 for eligibility criteria relevant to participants with type 2 diabetes

Primary outcome measure(s)

Trial sites (80)

FacilityCityRegionStatus
Clinical Research Institute of Arizona (CRI) - Sun City West Sun City West Arizona
Novak Clinical Research - Tucson - North La Cholla Boulevard Tucson Arizona
Norcal Endocrinology & Internal Medicine San Ramon California
Southern California Clinical Research Santa Ana California
Care Access - Thousand Oaks Thousand Oaks California
Accel Research Sites - DeLand Clinical Research Unit DeLand Florida
Innovation Medical Research Center - Fort Lauderdale Fort Lauderdale Florida
Indago Research & Health Center, Inc Hialeah Florida
Encore Medical Research Hollywood Florida
West Orange Endocrinology P.A. Ocoee Florida
Care Access - Tampa Tampa Florida
Conquest Research Winter Park Florida
Accel Research Sites - NeuroStudies Clinical Research Unit Decatur Georgia
Care Access - Decatur Decatur Georgia
Javara - Privia Medical Group Georgia - Savannah Savannah Georgia
North Georgia Clinical Research Woodstock Georgia
Solaris Clinical Research Meridian Idaho
Care Access - New Iberia New Iberia Louisiana
Endocrine and Metabolic Consultants Rockville Maryland
Javara - Privia Medical Group - Silver Spring Silver Spring Maryland
Great Lakes Research Group, Inc. Bay City Michigan
Boeson Research MSO Missoula Montana
Javara - Nevada Health Centers - Carson City Carson City Nevada
The Machuca Foundation Las Vegas Nevada
University of North Carolina Medical Center Chapel Hill North Carolina
Javara - Tryon Medical Partners Charlotte North Carolina
Care Access - Fayetteville Fayetteville North Carolina
The Corvallis Clinic, P.C. Corvallis Oregon
Clinical Research of Philadelphia Philadelphia Pennsylvania
Frontier Clinical Research, LLC Smithfield Pennsylvania
Velocity Clinical Research, Dallas Dallas Texas
Biopharma Informatic, LLC Houston Texas
Activian Clinical Research Kingwood Texas
Texas Valley Clinical Research (TVCR) - Mission Mission Texas
Consano Clinical Research, LLC Shavano Park Texas
CARE - Centro de Alergia y Enfermedades Respiratorias Buenos Aires Argentina
CIPREC Buenos Aires Argentina
Centro Médico Viamonte Buenos Aires Argentina
Instituto Centenario CABA Argentina
Instituto Médico Catamarca IMEC Rosario Argentina

+ 40 more sites — see the full list on the official registry below.

More Eli Lilly and Company trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06993792 on ClinicalTrials.gov ↗ ← All trials in the USA